CYP3A4、CYP3A5基因多态性与紫杉醇疗效及不良反应的相关性研究  

Research on the Correlation between CYP3A4 and CYP3A5 Gene Polymorphism and the Efficacy and Adverse Reactions of Paclitaxel

作　　者：许秋霞[1] 陈金成[1] 何少斌 陈文发[1] 吴沁 林珊珊 XU Qiu-xia;CHEN Jin-cheng;HE Shao-bin;CHEN Wen-fa;WU Qin;LIN Shan-shan(Laboratory of Clinical Pharmacy,Department of Pharmacy,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Pharmacy,Fujian Provincial Hospital,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属第二医院药学部临床药学实验室,福建泉州362000 [2]福建省立医院药学部,福建福州350001

出　　处：《海峡药学》2024年第5期96-98,共3页Strait Pharmaceutical Journal

基　　金：福建省科技创新联合资金项目资助(2023Y9241);泉州市引进高层次人才团队基金资助项目(2023CT008)。

摘　　要：目的探讨CYP3A4、CYP3A5基因多态性对紫杉醇疗效及不良反应的影响。方法选择我院2016年2月~2020年2月接受紫杉醇化疗的肿瘤患者67例作为研究对象,检测其CYP3A4*1G、CYP3A5*3基因型,并将患者分为野生型组和突变型组。2周期后,对疗效和药物不良反应进行评估,分析患者的疗效及不良反应和CYP3A4*1G、CYP3A5*3基因多态性的相关性。结果67例肿瘤患者中,CYP3A4*1G、CYP3A5*3基因的野生型组、突变型组之间的疗效和不良反应指标均不存在显著性差异(P>0.05)。结论CYP3A4*1G、CYP3A5*3基因多态性与紫杉醇的疗效和不良反应不具有相关性。OBJECTIVE To investigate the association between CYP3A4 and CYP3A5 gene polymorphism and the efficacy and adverse reactions of paclitaxel in patients with tumor.METHODS Sixty-seven patients who received paclitaxel chemotherapy from February 2016 to February 2020 were selected as experimental subjects,the CYP3A4*1G and CYP3A5*3 genotypes were detected,and the patients were divided into wild type group and mutant group.After 2 cycles,the efficacy and adverse drug reactions were evaluated,and the correlation between the efficacy and adverse drug reactions of patients and the polymorphism of CYP3A4*1G and CYP3A5*3 gene was analyzed.RESULTS Among 67 tumor patients,there was no significant difference between wild type group and mutant group of CYP3A4*1G and CYP3A5*3 in efficacy and adverse reactions(P>0.05).CONCLUSION CYP3A4*1G and CYP3A5*3 gene polymorphisms were irrelative with the efficacy and adverse reactions of paclitaxel.

关 键 词：CYP3A4 CYP3A5 基因多态性 紫杉醇 疗效 不良反应 

分 类 号：R969.3[医药卫生—药理学]